Evidence map›Paper›PMID 41013327›Full record

SynthesisBMC gastroenterology2025

Chemerin as a biomarker of inflammatory bowel diseases: a meta-analysis.

Zhi Tian, Qun Xiang, Meichun Long, Jiangtao Liao, Fang Wang, Xuefeng Li

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhi TianDepartment of Gastroenterology, People's Hospital of Xiangxi Autonomous Prefecture / The First Affiliated Hospital of Jishou University / Clinical College of Jishou University, Jishou, 416000, China.
Qun XiangDepartment of Gastroenterology, People's Hospital of Xiangxi Autonomous Prefecture / The First Affiliated Hospital of Jishou University / Clinical College of Jishou University, Jishou, 416000, China.
Meichun LongDepartment of Gastroenterology, People's Hospital of Xiangxi Autonomous Prefecture / The First Affiliated Hospital of Jishou University / Clinical College of Jishou University, Jishou, 416000, China.
Jiangtao LiaoDepartment of Digestive Diseases, People's Hospital of Hunan Province, Changsha, 410021, China.
Fang WangDepartment of Gastroenterology, People's Hospital of Xiangxi Autonomous Prefecture / The First Affiliated Hospital of Jishou University / Clinical College of Jishou University, Jishou, 416000, China. wangfang_xxph@hotmail.com.
Xuefeng LiDepartment of Gastroenterology, People's Hospital of Xiangxi Autonomous Prefecture / The First Affiliated Hospital of Jishou University / Clinical College of Jishou University, Jishou, 416000, China. xuefengli_xxph@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChemerin, an adipokine involved in immune regulation and inflammation, has been implicated in the pathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). However, existing studies have reported inconsistent findings regarding its diagnostic value. This meta-analysis aimed to clarify the association between blood chemerin levels and IBD.

methodsA systematic search was conducted in PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) up to February 10, 2024. Observational studies comparing blood chemerin levels between IBD patients and healthy controls, or between active and non-active IBD, were included. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random-effects model by incorporating the possible influence of the heterogeneity.

resultsTen case-control studies with 18 datasets involving 799 CD patients, 520 UC patients, 609 healthy controls, were included. Compared with healthy controls, IBD patients had significantly higher blood chemerin levels (SMD: 0.61, 95% CI: 0.46–0.76, p < 0.001; I² = 48%). This association remained consistent across subgroups by disease type, study quality score, study region, and BMI matching (p for subgroup difference all > 0.05). Furthermore, chemerin levels were higher in active versus non-active IBD patients (SMD: 0.36, 95% CI: 0.15–0.57, p < 0.001; I² = 38%), with robust findings across subgroup and sensitivity analyses. No significant publication bias was detected.

conclusionsElevated blood chemerin levels are associated with both the presence and activity of IBD, supporting its potential role as a non-invasive biomarker for disease diagnosis and monitoring.

Indexed as

ChemokinesColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesIntercellular Signaling Peptides and ProteinsBiomarkersCase-Control StudiesHumansBiomarkersChemokinesIntercellular Signaling Peptides and ProteinsRARRES2 protein, humanChemerinCrohn’s diseaseInflammatory bowel diseaseMeta-analysisUlcerative colitis

Identifiers

PMID41013327
PMCPMC12465509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.